Navigation Links
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Date:5/3/2011

SAN MATEO, Calif., May 3, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.  The trial is being conducted pursuant to Nile's previously announced collaboration with Medtronic and is the first clinical step towards developing cenderitide as a treatment for the post-acute heart failure space, a strategy which was recently granted Fast Track status by the United States Food and Drug Administration (FDA).

"This clinical trial signals the beginning of a new paradigm in the development of therapies for heart failure patients," said James Young, MD Professor and Executive Dean, Cleveland Clinic Lerner College of Medicine. "Administration of cenderitide on an outpatient basis could change how heart failure patients are treated and has the potential to reduce re-hospitalizations by targeting multiple aspects of the heart failure disease process."

The Phase I clinical trial is a placebo-controlled study designed to evaluate pharmacokinetic and pharmacodynamic actions of cenderitide when administered to chronic heart failure patients as a subcutaneous infusion or as a subcutaneous bolus injection. In the first part of the trial, patients will receive two subcutaneous bolus injections of cenderitide.  In the second part of the trial, patients will receive either a 24 hour continuous infusion of cenderitide or placebo, delivered through Medtronic's subcutaneous pump technology. The primary purpose of the trial is to understand the doses required to achieve pre-determined plasma levels of cenderitide delivered through a subcutaneous infusion pump and the pharmacodynamic activity at these doses.

"This clinical trial is a key first step in our post
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DALLAS , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty ... data on the Fatty Liver Disease clinical trial scenario. ... the clinical trials on Fatty Liver Disease . ... their recruitment status as per the site of trial ... coverage of disease clinical trials by their phase, trial ...
(Date:8/27/2014)... -- Ambit Biosciences (Nasdaq: AMBI ), a biopharmaceutical company ... in oncology, autoimmune and inflammatory disease, today announced the Company,s ... held at The New York Palace Hotel in ... Alan Fuhrman , Ambit,s CFO, will provide an ... at 1:10 p.m. ET on Wednesday, September 3, 2014.  The ...
(Date:8/27/2014)... REDWOOD CITY, Calif. , Aug. 27, 2014 ... in emergency response system design, blended emergency medical ... for CPR/AED (automated external defibrillator) training from the ... and the Army Reserve 81 st ... Homeland Security and Investigations contract includes nationwide CPR/AED/First ...
Breaking Medicine Technology:Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Ambit Announces Participation At Baird 2014 Health Care Conference 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3
... March 1, 2011 Heska Corporation (Nasdaq: ... and specialty products to veterinarians, today announced the addition ... in-clinic blood analyzers. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ... analyzer is used to measure lactate, and is ideal ...
... successful contract packaging and re-packaging companies in the ... new, single-source industry leader called Aphena Pharma ... corporation based on a strategic alliance between Celeste ... Packaging; all long-term specialized leaders in the contract ...
Cached Medicine Technology:Heska Introduces New Lactate Meter Analyzer 2Merger of Four Pharmaceutical Companies Announced 2
(Date:8/27/2014)... Overcoming a turbulent past which branded KC Armstrong ... Women’s Radio Network, WRNW1, has recently signed a multi-million dollar ... to the WRNW1 family. KC states, “it is such a ... atmosphere.” After KC Armstrong publicly announced his appreciation to Howard ... show, “Howard 100 News,” have decided to pay it forward. ...
(Date:8/27/2014)... IntelliSoft Group, LLC, a leading provider of ... IntelliCred, IntelliApp and IntelliContract Version 14.2 ... (NHAMSS) Annual Conference on September 16, 2014 at the ... Notable improvements available in IntelliSoft’s Version 14.2 ... Linking: A new Contract Connection Tab connects the healthcare ...
(Date:8/27/2014)... Time to Play Golf, a fast-growing golf ... , With 80-degree temperatures and only partially clouded skies, the ... Inaugural Outing. Around 50 golfers showed up to duel it ... Heron Glen Golf Course in Ringoes, New Jersey. , The ... be having a great time. Birdies were dropping and those ...
(Date:8/27/2014)... Los Angeles, California (PRWEB) August 27, 2014 ... unveiled its “Journey Candle Collection” to provide a growing number ... executives a scent-based tool for goal setting and relaxing at ... of six soy candles, uses scent memory and visualization to ... milestone in their life each time they light a candle ...
(Date:8/27/2014)... 2014 Michael A. Bottar ... of The Best Lawyers In America© for the practice ... Injury Litigation - Plaintiffs." , Bottar received his undergraduate ... laude graduate of Syracuse University College of Law where ... Practice" chapter of the Syracuse Law Review Survey of ...
Breaking Medicine News(10 mins):Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:Michael A. Bottar Selected For Inclusion In The Best Lawyers In America© 2015 2
... 25 WellPoint, Inc. (NYSE:,WLP) announced today that ... Healthcare Conference on January 30, 2008. The presentation ... Time., All interested parties are invited to ... http://www.wellpoint.com and selecting the "Investor,Info" link. ...
... 25, 2008 Researchers from Mayo Clinic in ... stents (SEPSs) in the treatment of benign esophageal disease ... stent migration and few cases of long-term improvement. They ... patient populations and to guide future recommendations for the ...
... must pass more than lip service reform in wake ... The following is a,statement by Executive Director, Kurt Entsminger, ... are among the most restrictive,in the nation. To get ... by the symptoms of an illness like,schizophrenia to be ...
... Bill Novelli,made the following statement about next Monday,s vote on ... by the California State Senate,Committee on Health:, "On behalf ... the members of the State Senate Health Committee to pass ... Monday. ABX 1 1 represents a major step toward,ensuring that ...
... Inc. ("Assurant"),(NYSE: AIZ ), a premier provider of ... its board of,directors has declared a quarterly dividend of ... March 10, 2008 to shareholders of record as of,Feb. ... at the discretion of the,board of directors and will ...
... 25, 2008 --New York, NY-- Researchers in Belgium have ... with the capacity to generate new insulin-producing beta cells. ... the newfound progenitor cells may represent an obvious target ... researchers report in the Jan. 25 issue of the ...
Cached Medicine News:Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 3Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 2Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 3Health News:Elusive pancreatic progenitor cells found in mice 2
... The Bio-Optics LSM-12000 is a new ... powerful new tool in anterior segment diagnostics ... easy to operate, easy to maintain, and ... is the only High Magnification Slit-Lamp Biomicroscope ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... a rapid field or laboratory test for the ... simple, two-step test provides results in 10 minutes, ... , ,Intended use: The NOW® Hepatitis B sAg/eAg ... the detection of Hepatitis B surface antigen (HBsAg) ...
... the newest technology available in acrylic lens ... exceptional material and design properties to achieve ... , Unique foldable hydrophobic acrylic material ... biostable , High index of refraction ...
Medicine Products: